Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 215, Issue 9, Pages 2265-2278Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20172323
Keywords
-
Categories
Funding
- National Institutes of Health [AI072571, AG049074, AI115382, AI100853, AI124661, AI134040]
- Dr. Bernard Levine Postdoctoral Fellowship in Immunology
Ask authors/readers for more resources
An IRF8-dependent subset of conventional dendritic cells (cDCs), termed cDC1, effectively cross-primes CD8(+) T cells and facilitates tumor-specific T cell responses. Etv6 is an ETS family transcription factor that controls hematopoietic stem and progenitor cell (HSPC) function and thrombopoiesis. We report that like HSPCs, cDCs express Etv6, but not its antagonist, ETS1, whereas interferon-producing plasmacytoid dendritic cells (pDCs) express both factors. Deletion of Etv6 in the bone marrow impaired the generation of cDC1-like cells in vitro and abolished the expression of signature marker CD8 alpha on cDC1 in vivo. Moreover, Etv6-deficient primary cDC1 showed a partial reduction of cDC-specific and cDC1-specific gene expression and chromatin signatures and an aberrant up-regulation of pDC-specific signatures. Accordingly, DC-specific Etv6 deletion impaired CD8(+) T cell cross-priming and the generation of tumor antigen-specific CD8(+) T cells. Thus, Etv6 optimizes the resolution of cDC1 and pDC expression programs and the functional fitness of cDC1, thereby facilitating T cell cross-priming and tumor-specific responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available